@Article{info:doi/10.2196/64611,
author="Byrom, Bill
and Everhart, Anthony
and Cordero, Paul
and Garratt, Chris
and Meyer, Tim",
title="Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials",
journal="JMIR Cancer",
year="2025",
month="Feb",
day="28",
volume="11",
pages="e64611",
keywords="clinical trials; early phase; dose finding; patient-reported outcome; PRO; electronic patient-reported outcome; ePRO; PRO-CTCAE; adverse events; tolerability; optimal dose; cancer trials; dose toxicity; oncology; drug development; electronic collection; dose level; pharmacodynamic; cytotoxic chemotherapy drugs; cytotoxic; chemotherapy drug; life-threatening disease; Common Terminology Criteria for Adverse Events",
issn="2369-1999",
doi="10.2196/64611",
url="https://cancer.jmir.org/2025/1/e64611",
url="https://doi.org/10.2196/64611"
}